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toma (NB) and Ewing’s sarcoma (ES) have dismal prognosis
(Perkins et al, PLoS One, 2014). Targeted cellular therapy with
T or NK cells modified with chimeric antigen receptors (CAR)
is a novel approach to chemo-resistant childhood solid tu-
mors (Grupp SA, Clin Cancer Res, 2012; Mackall C, Front Oncol,
2012). NK cells can be significantly expanded by co-culture
with genetically engineered K562 cells overexpressing mb-
IL21 (Lee D, PLOS, 2012). Riddell and colleagues have iden-
tified ROR1 as a novel target on B cell tumors in which CARs
can be developed and utilized for targeted cellular therapy
(Riddell S, Blood, 2010).
Objective: To evaluate the in-vitro NK cytotoxic activity and
NK cell function following ex-vivo K562 mb-IL21expansion
of PBNK nucleofected with anti-ROR1-CAR against NB and
ES.
Material and Methods: PBNK were expanded with lethally
irradiated K562 Clone 9.mb-IL21 (generously provided by
Lee D, MD, PhD, MD Anderson, TX). Ex-vivo expanded PBNK
(ExPBNK) cells were electroporated with anti-ROR1-CD28-
41BBl-CD3z-tEGFRemRNA (Anti-ROR1-CAR was generously
provided by Riddell S, MD, Fred Hutch, WA). Anti-ROR1-CAR-
NK expression was detected using anti-mouse IgG, F(ab’)2.
Anti-ROR1-CAR-NK cytotoxicity was investigated against NB
(SKNBE2, SKNFI & SHSY5Y) and ES (TC71, EWS 502 & A673)
cell lines by DELFIA cytotoxicity assay at 10:1 E: T ratio.
Intracellular staining of CD107a, Interferon Gamma, Perforin
and GranzymeB was performed using a 10:1 E:T ratio of anti-
ROR1-CAR-NK cells against tumor targets & analyzed on the
MACSQuant flow cytometer.
Results: NB and ES cell lines expressed ROR1 (50.215.6%)
and (31.512%), respectively. Expansion of NK cells was
significantly increased 3988435 fold (p¼0.00001) at day
14 vs day 0. Nucleofection success was measured by F(ab’)2
expression and showed a significant increase in anti-
ROR1-CAR- (88.31.69%) vs Mock-electroporated NK cell
populations (8.16.9%) p¼ 0.0001 at 36-48 hours (Figure 1).
ROR1 negative A673 served as negative control. Anti-ROR1-
CAR-NK significantly increased cell lysis compared to
Mock NK (93.11.9% vs 62.85.2%, p¼0.0008) against
ROR1expressing cell lines at 10:1 ET ratio (Figure 2).
Similarly, expression of CD107a (46.92.2 vs 26.93%)
p¼0.0004, Interferon Gamma (36.912.4vs15.36.9%)
p¼0.008, GranzymeB (62.84.4 vs 46.67.7%) p¼0.003,
and Perforin (50.58 vs 32.714.1%) p¼0.004 were
significantly increased in anti-ROR1-CAR-NK vs Mock-NK
cells at 10:1 E:T ratio against the ROR1 expressing targets.
Conclusion: Anti-ROR1-CAR-ex-PBNK cells had significant
enhanced cytotoxicity and significantly increased CD107a,
Interferon Gamma, Perforin, and GranzymeB activity against
ROR1 expressing pediatric solid tumors. Future directions
include investigating the ex-PBNK anti–ROR1-CAR cells in-
vivo against ROR1 expressing pediatric solid tumors.95
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Hematopoietic Stem Cell Transplantation (HSCT) is curative in
a large number of primary immunodeficiencies (PID). The first
transplant in PID in Brazil was held in 1992 at the Hospital de
Clínicas da Universidade Federal do Paraná. Since then, in
Brazil, only few centers have performed transplants in these
pathologies. Objective: Retrospective analysis of outcomes of
HSCT performed in patients with PID in 10 Brazilian centers
participating in theworking group of pediatric transplantation
of the Brazilian Society of BMT (SBTMO). From 1992 to April
2014, 166 patients underwent HSCT on PID in 10 different
centers in Brazil, mostly in the Hospital of UFPR (n ¼ 90), fol-
lowed by the Hospital Israelita Albert Einstein (n¼ 27) and the
other centers with 10 or fewer. Most patients were male (M ¼
130, F¼ 36), andmost patients had age lower than3 years (n¼
119). The diagnoses were distributed among: Wiskott-Aldrich
syndrome (n¼ 56); Severe Combined Immunodeficiency (n¼
52); Chronic granulomatous disease (n¼ 14); Familiar Hemo-
phagocytic lymphohistiocytosis (n ¼ 13); Chediak-Higashi
Syndrome (n ¼ 12); Hyper-IgM syndrome (n ¼ 5); Severe
congenital neutropenia (n ¼ 5); IPEX syndrome (n ¼ 3); com-
bined immunodeficiency disease (n¼ 2); Leukocyte Adhesion
Deficiency (n ¼ 2); Deficiency of IFN-gamma (n ¼ 1) and
Griscelli syndrome (n ¼ 1). Thirty-two patients received
transplants from identical sibling donors, 112 unrelated do-
nors, and 22 other family donors (10/10 compatible or hap-
loidentical). Graftwas bonemarrow in 84 cases, umbilical cord
blood in 78 cases and 4 patients received stem cells from pe-
ripheral blood. Ninety-nine patients received myeloablative
transplants (including busulfan>8mg/Kg), 55 patients
received reduced toxicity conditioning and 12 patients
received no conditioning. The prophylaxis of graft-versus-host
disease was performed with cyclosporine A in most cases,
associated with mycophenolate mofetil, methotrexate or ste-
roids. Overall survival was 68.7% at 3 years. In univariate
analysis, there was no statistical difference between gender,
diagnosis, age at HSCT, year of transplant, source of cells, or
donor type. Among the most frequent pathologies groups,
analysis was done in 2 groups, the severe combined immu-
nodeficiency (n¼ 52) and theWiskott-Aldrich syndrome (n¼
56) Syndrome. In these subgroups, the overall survival at 3
years was 60% and 79%, respectively.
Conclusion: This is the first survey made on transplants on
primary immunodeficiencies in Brazil. Despite the diffi-
culties in diagnosing and referral of these children for special
treatment in our country, we have seen that the overall
survival of our patients is not different than those reported in
international studies in Europe or North America. This survey
is extremely important to have the results of these cases in
Brazil, and identify areas to improve the outcomes of trans-
plants in lower income countries.
Figure. Genetic variations in complement associated genes (HSCT recipient DNA). Figure shows a “heat map” of gene variants in recipients with and without TMA: each
column represents a gene,with heterozygous variants shaded light blue and homozygous variants shaded red. Each row is a single patient, illustrating thewide distribution
of variants in multiple genes in the TMA cases, while few variants are seen in the cases without TMA.
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Background: Transplant associated thrombotic micro-
angiopathy (TMA) is frequent after HSCT, and in severe cases
causes significant morbidity and mortality. Currently there
are no data addressing individual susceptibility to transplant
associated TMA. Frequent genetic variants in ADAMTS13 and
complement genes have been described in other micro-
angiopathies such as aHUS and TTP. We hypothesized that
polymorphic variants in complement genes increase sus-
ceptibility to transplant associated TMA.
Methods: 90 consecutive allogeneic HSCT patients were
enrolledonaprospective TMAbiomarker studyand categorized
as having TMA or no TMA using rigorous diagnostic criteria
(Jodele et al, Blood 2014). Genomic DNAwas isolated from pre-
HSCT recipient blood. We used a candidate gene approach to
identify 12 geneswithin the complement pathway likely to play
a role in terminal complement activation, the likely effector
mechanism for vascular damage in TMA. All exons, flanking
intronic and untranslated regions of ADAMTS13, CFH, CFI, CFB,
MCB, THBD, C3, C5, CFD, CFHR1, CFHR3 and CFHR5 were
sequenced using next generation sequencing technology. The
resulting sequence reads were aligned against the reference
DNA sequence and the variants were detected using NextGENesoftware. Observed variants were compared against dbSNP
(NCBI). Novel variants were further evaluated using laboratory
developed bioinformatic tools. Eight variants previously
described as likely pathogenic and 34 variants of unknown
pathogenic significancewere identified. Resultswere compared
in patients with and without TMA.
Results: 77 patients had DNA available for analysis (34 with
TMA and 43 without TMA); 23 of 34 (68%) subjects with TMA
had complement gene variants as compared to 4 of 43 (9%)
controls without TMA (p<0.0001). Figure shows a “heat map”
of gene variants in recipients with and without TMA
illustrating the wide distribution of variants in multiple
genes in the TMA cases, while few variants are seen in those
without TMA. Likely pathogenic variants previously
described in other microangiopathies were seen in
ADAMTS13 (n¼2), CFH (n¼2), CFB (n¼1), CFHR5 (n¼1) and
CFI (n¼3), all in recipients with TMA. No known pathogenic
variants were seen in subjects without TMA. Two recipients
with TMA had homozygous deletion of CFHR3/R1, which was
not seen in the recipients without TMA. The median number
of gene variants (of known or unknown significance) seen in
recipients with TMAwas 1 (0-7), and 0 (0-2) in those without
TMA (p<0.0001). Two subjects had 5 variants and one 7
variants and all three had fatal TMA.
Conclusion: The incidence of complement gene variants was
higher in patients with TMA as compared to patients without
TMA, indicating that genetic susceptibility importantly alters
risk. Additional larger studies are needed to define the
mechanistic importance of variants of unknown clinical
significance.
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